

CERTIFICATE

Survey of 15 March 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Fecal Diagnostics 01 - Calprotectin (130):

Validity 12 months:

Calprotectin
Fecal Elastase

(R) analysis is subject to the RiliBÄK

Customer:
10011854
Dr. Steffen Spranger
Labor Dr. Spranger und Kollegen
Lindberghstr. 9-13
85051 Ingolstadt

Düsseldorf, 03 April 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 15 March 2024

You have participated in the External Quality Assessment with the following analysis

Fecal Diagnostics 01 - Calprotectin (130):

Calprotectin
Fecal Elastase

(R) analysis is subject to the RiliBÄK

Customer:
10011854
Dr. Steffen Spranger
Labor Dr. Spranger und Kollegen
Lindberghstr. 9-13
85051 Ingolstadt

Düsseldorf, 03 April 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)



Listing and evaluation of the results

10011854: Dr. Steffen Spranger
Labor Dr. Spranger und Kollegen

Survey of 15 March 2024

Adviser:

Prof. Dr. rer. nat. Dr. med. Jürgen Durner
Labor Becker MVZ GbR
Führichstr. 70
81671 München

Tel.: +49 89 450 917 349
Fax: +49 89 450 917 6349
Mail: j.durner@labor-becker.de

130

Fecal Diagnostics 01 - Calprotectin

Analyte	Sam- ple	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Calprotectin	21	mg/kg	9.81		ET		<=50.0		-0,605	+	
	22		155	214	SV	118	310	-27.5%	-0,992	+	
Fecal Elastase	21	µg/g	42.5	59.3	SV	32.6	86.0	-28.3%	-0,874	+	
	22		321	401	SV	221	581	-19.9%	-0,781	+	

Analyte	Sam- ple	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device	Lot number
Calprotectin	21		9.81	1.00	64	IK	MK02	
	22		155	1.00				
Fecal Elastase	21		42.5	1.00	64	IK	MK02	
	22		321	1.00				

Additional information on the evaluation is available for download in the RV-Online system in the column "Report".

Individual summary of results

10011854: Dr. Steffen Spranger
Labor Dr. Spranger und Kollegen



Survey of 15 March 2024

130

Fecal Diagnostics 01 - Calprotectin

Calprotectin (mg/kg, N = 317)									
Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
R-BIOPHARM	21		- <=50.0	19.5	0.000	8	87.5	75.0	
	22	296	163 - 429	296	36.5	8	75.0		
BÜHLMANN	21		- <=50.0	23.9	30.3	50	98.0	86.0	
	22	378	208 - 548	378	27.5	50	86.0		
DIASORIN	21		- <=50.0	5.00	0.000	117	99.1	87.2	
	22	203	112 - 294	203	22.1	117	87.2		
IMMUNDIAGNOSTIK	21		- <=50.0	13.5	45.2	30	100	86.7	
	22	214	118 - 310	214	27.8	30	86.7		
THERMO / PHADIA	21		- <=50.0	5.98	53.5	35	97.1	68.6	
	22	308	169 - 447	308	42.9	35	68.6		
ORGENTEC	21		- <=50.0	0.100	0.000	9	88.9	66.7	
	22	644	354 - 934	644	46.6	9	77.8		
EUROSPITAL	21		- <=50.0	25.9	72.6	26	92.3	65.4	
	22	161	88.6 - 233	161	41.8	26	69.2		
SHEBO BIOTECH AG	21		- <=50.0	37.5	0.000	10	100	100	
	22	118	64.9 - 171	118	20.1	10	100		
others	21		- <=50.0	14.6	62.0	32	100	56.3	
	22	217	119 - 315	217	54.4	32	56.3		

Rate of success: 79,5%



Fecal Elastase (µg/g, N = 221)									
Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
Bioserv Diagnostics	21	134	73.7 - 194	134	54.9	10	60.0	60.0	
	22	431	237 - 625	431	30.9	10	90.0		
R-BIOPHARM	21	104	57.2 - 151	104	22.7	10	90.0	90.0	
	22	376	207 - 545	376	16.4	10	100		
IMMUNDIAGNOSTIK	21	59.3	32.6 - 86.0	59.3	32.4	20	95.0	95.0	
	22	401	221 - 581	401	25.4	20	100		
Diasorin	21	90.0	49.5 - 131	90.0	19.0	105	91.4	86.7	
	22	855	470 - 1240	855	24.7	105	93.3		
SCHEBO BIOTECH AG	21	105	57.8 - 152	105	41.0	41	75.6	75.6	
	22	667	367 - 967	667	0.000	41	95.1		
BÜHLMANN	21	70.8	38.9 - 103	70.8	29.2	19	89.5	89.5	
	22	530	292 - 867	530	27.9	19	100		
others	21	107	53.6 - 160	107	53.1	16	62.5	50.0	
	22	421	232 - 610	421	31.6	16	87.5		

Rate of success: 81,9%

